Arthur P. Bertolino
- Immunology top 2%
- Urology top 2%
- Hair Growth and Disorders 14
- Rheumatology top 2%
- Dermatology top 2%
- Dermatologic Treatments and Research 4
- Skin Protection and Aging 2
- Hematology top 5%
-
- Skin and Cellular Biology Research 9
- melanin and skin pigmentation 5
-
- Dyeing and Modifying Textile Fibers 4
-
- RNA regulation and disease 2
-
- Genetic and rare skin diseases. 2
- Co-authors
- Wolfgang HueberStephan BekMarc VandemeulebroeckeBrian G. FeaganSimon TravisJan WehkampMarek KarczewskiPeter Higgins
- Cited by
- ImmunologyUrologyRheumatology
- Partner nations
- United StatesUnited KingdomSwitzerland
In The Last Decade
Arthur P. Bertolino
20 papers receiving 1.7k citations
Hit Papers
Peers
Comparison fields: 5 of 104
- Immunology 1.0k
- Urology 197
- Rheumatology 433
- Dermatology 235
- Hematology 290
Countries citing papers authored by Arthur P. Bertolino
This map shows the geographic impact of Arthur P. Bertolino's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arthur P. Bertolino with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arthur P. Bertolino more than expected).
Fields of papers citing papers by Arthur P. Bertolino
This network shows the impact of papers produced by Arthur P. Bertolino. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arthur P. Bertolino. The network helps show where Arthur P. Bertolino may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Arthur P. Bertolino, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2013 | 272 | |
| 2 | Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trialbreakdown → | 2012 | 1156 |
| 3 | 2000 | 18 | |
| 4 | 2000 | 8 | |
| 5 | 1996 | 3 | |
| 6 | 1993 | 33 | |
| 7 | 1993 | 69 | |
| 8 | 1993 | 3 | |
| 9 | 1991 | 20 | |
| 10 | 1991 | 24 | |
| 11 | 1991 | 26 | |
| 12 | 1991 | 2 | |
| 13 | 1990 | 46 | |
| 14 | 1988 | 39 | |
| 15 | 1988 | 1 | |
| 16 | 1988 | 1 | |
| 17 | 1982 | 9 | |
| 18 | 1979 | 7 | |
| 19 | 1978 | 17 | |
| 20 | 1978 | 21 |
About Arthur P. Bertolino
Arthur P. Bertolino is a scholar working on Urology, Dermatology and Cell Biology, having authored 20 papers that have together received 1.8k indexed citations. Recurring topics across this work include Hair Growth and Disorders (14 papers), Skin and Cellular Biology Research (9 papers), melanin and skin pigmentation (5 papers), Dyeing and Modifying Textile Fibers (4 papers), Dermatologic Treatments and Research (4 papers), RNA regulation and disease (2 papers), Skin Protection and Aging (2 papers) and Genetic and rare skin diseases. (2 papers). The work is most often cited by research in Immunology (1.0k citations), Urology (197 citations) and Rheumatology (433 citations). Arthur P. Bertolino has collaborated with scholars based in United States, United Kingdom and Switzerland. Frequent co-authors include Wolfgang Hueber, Stephan Bek, Marc Vandemeulebroecke, Brian G. Feagan, Simon Travis, Jan Wehkamp, Marek Karczewski, Peter Higgins, Walter Reinisch and Gervais Tougas.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.